相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Hidetoshi Hayashi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Towards personalized treatment for early stage HER2-positive breast cancer
Kristina Goutsouliak et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells
Manuel A. Silva et al.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH (2020)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
Application of PD-1 Blockade in Cancer Immunotherapy
Xiaomo Wu et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Immunogenic cell death in cancer therapy: Present and emerging inducers
Jingyi Zhou et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation
Malgorzata Krajewska et al.
NATURE COMMUNICATIONS (2019)
Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
Oliver Kepp et al.
ONCOIMMUNOLOGY (2019)
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Alfonso Serrano-del Valle et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
Victor Quereda et al.
CANCER CELL (2019)
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Mario Giuliano et al.
LANCET ONCOLOGY (2019)
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Shixiang Wang et al.
ELIFE (2019)
Stem cell replication, somatic mutations and role of randomness in the development of cancer
Vittorio Perduca et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2019)
The Intriguing History of Cancer Immunotherapy
Paula Dobosz et al.
FRONTIERS IN IMMUNOLOGY (2019)
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer
Kenji Tamura
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium
Arno L. Greenleaf
TRANSCRIPTION-AUSTIN (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy
Flavia Radogna et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins
Jingshan Tong et al.
CANCER RESEARCH (2018)
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Dewan Md Sakib Hossain et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies
Jacob P. van Vloten et al.
JOURNAL OF IMMUNOLOGY (2018)
Current status and future directions of cancer immunotherapy
Hongming Zhang et al.
JOURNAL OF CANCER (2018)
Further Advances in Cancer immunotherapy: Going Beyond Checkpoint Blockade
Robert W. Wilkinson et al.
FRONTIERS IN IMMUNOLOGY (2018)
Induction of enhanced immunogenic cell death through ultrasound-controlled release of doxorubicin by liposome-microbubble complexes
Feng-Ying Huang et al.
ONCOIMMUNOLOGY (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
CDK12: an emerging therapeutic target for cancer
Goldie Y. L. Lui et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Immunogenic effects of chemotherapy-induced tumor cell death
Yi-Jun Wang et al.
GENES & DISEASES (2018)
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
J. Tong et al.
ONCOGENE (2017)
Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes
Jingjing Zhu et al.
NATURE COMMUNICATIONS (2017)
Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis
P. Savola et al.
NATURE COMMUNICATIONS (2017)
Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells
Jingshan Tong et al.
CANCER RESEARCH (2017)
The UPR reduces glucose metabolism via IRE1 signaling
Judith M. van der Harg et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2017)
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
Joaquin Bellmunt et al.
CANCER TREATMENT REVIEWS (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Xu Zhou et al.
CURRENT DRUG METABOLISM (2016)
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Marcel A. Deken et al.
ONCOIMMUNOLOGY (2016)
Characterization of Human Cyclin-Dependent Kinase 12 (CDK12) and CDK13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and RNA Processing
Kaiwei Liang et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
eIF2α phosphorylation as a biomarker of immunogenic cell death
Oliver Kepp et al.
SEMINARS IN CANCER BIOLOGY (2015)
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D. Garg et al.
FRONTIERS IN IMMUNOLOGY (2015)
Molecular mechanisms of ATP secretion during immunogenic cell death
I. Martins et al.
CELL DEATH AND DIFFERENTIATION (2014)
Immunogenic Cell Death in Cancer Therapy
Guido Kroemer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients
Yvonne Nadine Fahmueller et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
James W. Hodge et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress
Brian F. Teske et al.
MOLECULAR BIOLOGY OF THE CELL (2011)
分享论文
